AIRLINK 81.10 Increased By ▲ 2.55 (3.25%)
BOP 4.82 Increased By ▲ 0.05 (1.05%)
CNERGY 4.09 Decreased By ▼ -0.07 (-1.68%)
DFML 37.98 Decreased By ▼ -1.31 (-3.33%)
DGKC 93.00 Decreased By ▼ -2.65 (-2.77%)
FCCL 23.84 Decreased By ▼ -0.32 (-1.32%)
FFBL 32.00 Decreased By ▼ -0.77 (-2.35%)
FFL 9.24 Decreased By ▼ -0.13 (-1.39%)
GGL 10.06 Decreased By ▼ -0.09 (-0.89%)
HASCOL 6.65 Increased By ▲ 0.11 (1.68%)
HBL 113.00 Increased By ▲ 3.50 (3.2%)
HUBC 145.70 Increased By ▲ 0.69 (0.48%)
HUMNL 10.54 Decreased By ▼ -0.19 (-1.77%)
KEL 4.62 Decreased By ▼ -0.11 (-2.33%)
KOSM 4.12 Decreased By ▼ -0.14 (-3.29%)
MLCF 38.25 Decreased By ▼ -1.15 (-2.92%)
OGDC 131.70 Increased By ▲ 2.45 (1.9%)
PAEL 24.89 Decreased By ▼ -0.98 (-3.79%)
PIBTL 6.25 Decreased By ▼ -0.09 (-1.42%)
PPL 120.00 Decreased By ▼ -2.70 (-2.2%)
PRL 23.90 Decreased By ▼ -0.45 (-1.85%)
PTC 12.10 Decreased By ▼ -0.89 (-6.85%)
SEARL 59.95 Decreased By ▼ -1.23 (-2.01%)
SNGP 65.50 Increased By ▲ 0.30 (0.46%)
SSGC 10.15 Increased By ▲ 0.26 (2.63%)
TELE 7.85 Decreased By ▼ -0.01 (-0.13%)
TPLP 9.87 Increased By ▲ 0.02 (0.2%)
TRG 64.45 Decreased By ▼ -0.05 (-0.08%)
UNITY 26.90 Decreased By ▼ -0.09 (-0.33%)
WTL 1.33 Increased By ▲ 0.01 (0.76%)
BR100 8,052 Increased By 75.9 (0.95%)
BR30 25,581 Decreased By -21.4 (-0.08%)
KSE100 76,707 Increased By 498.6 (0.65%)
KSE30 24,698 Increased By 260.2 (1.06%)

KARACHI: Pakistan’s pharmaceutical sector can increase its exports to $3 billion over the next five years, provided it gets policy support and a favourable business environment, according to a top official.

At a time when Pakistan is looking to create non-debt creating foreign exchange inflow, increasing exports is a low-hanging fruit, according to many experts.

India’s pharmaceutical exports are set to reach $28 billion in fiscal 2023-24, according to the Pharmaceutical Export Promotion Council (Pharmexcil), while Pakistan has only registered its personal best of $713 million during 2022-23.

However, the milestone will only be achieved if the government addresses the significant challenges facing the sector today, added the official.

Points to focus on

In an interview with Business Recorder, a former chairperson of the Pakistan Pharmaceutical Manufacturers Association (PPMA) highlighted the need for a more commercially aware drug regulatory authority and greater government support to boost exports.

The official emphasised that the Drug Regulatory Authority (DRAP) lacks commercial understanding, which hinders its ability to facilitate exports. The official also urged DRAP to collaborate with the Trade Development Authority (TDAP) and the Ministry of Commerce to address this issue. “DRAP is a technical department with technical people like pharmacists and doctors working in key positions,” said the official.

“Technically, they are doing a wonderful job, but they don’t have commercial understanding of the industry, which makes it difficult for them to facilitate exports.”

The official also stressed the need for increased liquidity to maintain foreign teams and promote Pakistan-made drugs abroad. “It’s a difficult task to increase market share in other countries, and companies have to develop brands. It needs full teams to be maintained outside the country, which requires a lot of liquidity,” the official added.

To address these challenges, the former chairperson proposed increasing the retention rate of foreign exchange from 15% to 35% to facilitate payments abroad. The official also advocated for a market development assistance (MDA) system similar to India’s Pharmexil to support the industry.

It was also highlighted that a technical issue is hindering the industry’s growth – the 20% protective duty on imported Active Pharmaceutical Ingredients (APIs).

While the duty is intended to support local API production, it is actually making drug manufacturing more expensive and rendering Pakistani medicines uncompetitive in foreign markets.

“Putting duties on imported raw material is making drug manufacturing expensive, which in turn is making Pakistan medicines uncompetitive in the foreign markets,” the official said.

“For instance, the API for paracetamol is more expensive in Pakistan than it is in China. It eventually makes Pakistani paracetamol expensive in the international market, therefore uncompetitive.”

The official suggested that the government should facilitate API manufacturers through subsidies and incentives instead of imposing duties.

“The government needs to gauge local API production capacity first and take policy decisions on that basis.”

Furthermore, the official emphasised the need for a stable supply chain and reliable raw material procurement, which is crucial for securing long-term agreements in foreign markets.

“Foreign markets have agreements of years – up to seven years. Companies, therefore, need a stable supply chain – procurement of raw material, and on that basis, relying on local sources for APIs is a gamble,” the official said.

The comments underscore the need for a more supportive regulatory environment and increased government assistance to unlock the full potential of Pakistan’s pharmaceutical exports.

With Pakistan desperately looking at creating sources of foreign exchange inflow, increasing exports has been highlighted as a key area. Despite massive rupee depreciation over the last few years, exports have not nearly shown the kind of growth needed for an economy as big as Pakistan’s. Hence, experts believe, there are several other avenues that need to be focused on as Pakistan looks to bring in non-debt creating foreign exchange.

Copyright Business Recorder, 2024

Comments

Comments are closed.

Usman May 17, 2024 07:30am
If govt support is to give subsidies in different form than NO.it should not happen.Pharma sector has madr billions.Should raise money from banks locally or internationally.no more taxpayers funding
thumb_up Recommended (0)
Irfan May 17, 2024 12:19pm
Focus should be on removing hurdles in prod of local APIs instead of saying "relying on local sources for APIs is a gamble,” With depreciation of our PKR relying on imported API is a bigger gamble.
thumb_up Recommended (0)
Dr Rahmatullah May 17, 2024 12:36pm
Invite Chinese manufacturers.Chinese should enter Pakistan at the earliest.
thumb_up Recommended (0)
test May 17, 2024 02:22pm
Chinese Sinopharm revenue 80 billion usd US Pfizer revenue 60 billion usd Swiss Novartis revenue 50 billion usd UK AstraZeneca revenue 50 billion usd They import cheap API & export expensive medicine.
thumb_up Recommended (0)
test1 May 17, 2024 02:23pm
@Usman, Exactly no more subsidies.
thumb_up Recommended (0)
Re=== May 18, 2024 07:12am
@Dr Rahmatullah, We have been inviting Chinese business for several years, they do not want to come. We think of them like our uncle who will come and give money anytime.
thumb_up Recommended (0)
Aam Aadmi May 18, 2024 12:46pm
Ineffective, worthless pharma! Who would buy these drugs made in Pakistan while there is always a shortage of essential drugs in the country.
thumb_up Recommended (0)
Dr Munir Akram May 18, 2024 12:47pm
@Re===, not just inviting, we need to buy Chinese products. Abolish anti dumping duties on Chinese origin products. Chinese industries will slowly follow.
thumb_up Recommended (0)
Dr Munir Akram May 18, 2024 12:51pm
To bring Chinese investments, first become a market for Chinese products.
thumb_up Recommended (0)
Dr Munir Akram May 18, 2024 12:54pm
Chinese participation would make pharmaceutical industry a competitive one. When you compete with the best, local citizens reap rich benefits.
thumb_up Recommended (0)